The methylation of lysine residues is an important posttranslational modification that occurs in histone proteins in the nucleosome as well as in non-histone proteins. The process is dynamically reversible through the action of lysine demethylases (KDMs), a family of enzymes that are further subdivided into the lysine-specific demethylases (KDM1, two human isoforms LSD1 and LSD2) and the Jumonji C demethylases (KDM2-7, over twenty human isoforms). 1 Historically, LSD1 was the first demethylase to be discovered and is recruited to the nucleosome as a component of diverse multi-protein complexes. Depending on the context and splice variant, LSD1 can exert either an activating or repressive effect on gene transcription by the demethylation of histone H3K4, H3K9 or H4K20 lysine residues. [2] [3] [4] Although LSD1 is essential for normal function, its dysregulation in cancer, CNS disorders and viral infection has propelled interest in LSD1 as a drug discovery target. LSD1 shares a mechanistic homology with monoamine oxidase (MAO) as both enzymes cleave a substrate C-N bond to give the dealkylated amine and an aldehyde using FAD as an oxidizing cofactor (Fig 1) . A number of diverse small molecule leads targeting LSD1 have been reported. 5, 6 Some well-established MAO inhibitors also inhibit LSD1 among which the approved antidepressant tranylcypromine 1 (Fig 2) is the best characterized, acting as a suicide substrate that undergoes ring opening to iminium radical 2 that covalently modifies and inactivates the FAD cofactor. Through LSD1 inhibition, tranylcypromine promotes differentiation in acute myeloid leukemia (AML) cells to overcome their resistance to all-trans-retinoic acid (ATRA). 7 Consequently, the drug is undergoing repositioning as an anticancer agent and clinical trials in combination with ATRA are underway. Meanwhile, as tranylcypromine itself is relatively modest in LSD1 inhibition (IC 50 ~ 25 µM), medicinal chemistry efforts have focused on second-generation analogues with higher potency. Despite the mechanistic similarity between amine oxidases, the structure-activity relationships among tranylcypromine analogues is distinct for MAOs versus LSD1. For example, we found that a cyclopropylamine bearing an alkoxy substituent in lieu of the aromatic ring in 1 was a nanomolar MAO inhibitor but inactive against LSD1. 21 In the present study, we were interested in the feasibility of incorporating cyclopropyl ring fluorination in tranylcypromines. While selected examples were previously reported as MAO inhibitors, 22, 23 this type of substitution pattern had not been explored for LSD1 inhibition.
In preliminary experiments, we examined the N-benzyl derivative 3 (Fig 3) of monofluorinated tranylcypromine and homologated analogues 4 and 5 that contain a spacer between the amine and the cyclopropyl ring. In a fluorescence-based LSD1 enzyme assay that monitors H 2 O 2, the product of FAD turnover, through its reaction with Amplex Red, 12 these compounds did not significantly inhibit LSD1 at a concentration of 25 µM (the IC 50 of tranylcypromine). The results are consistent with earlier studies by Burger and Haufe where 3-5 or their non-fluorinated congeners were inactive against MAOs. 22, 24 Interestingly, the diphenyl analogue 6 was more potent than tranylcypromine with an IC 50 2.1 ± 0.8 µM. Moreover, this is an increase by an order of magnitude compared to the activity against MAO A (IC 50 18 ± 3 µM) or MAO B (IC 50 37 ± 2 µM). 23 Overall, the experiments suggested that fluorination can be tolerated in the tranylcypromine scaffold for LSD1 inhibition. Since many analogues with a higher level of activity than the parent drug feature aromatic ring substitution, we next turned to compounds that contained additional functionalization of the benzene ring. We investigated a series of twenty-seven fluorinated tranylcypromines 7-10 (Fig 4) in which the phenyl ring contained electron donating or electron withdrawing substituents in the para or meta-position. Compounds 7-10 were prepared from the corresponding α-fluorostyrenes through a four step procedure (details in the Supporting Material) involving Cu(I)-catalyzed cyclopropanation with diazoacetates, ester saponification to the acids, Curtius rearrangement of the acids to Boc-amines and deprotection of the Boc group. 22, 23, 25 For the majority of compounds, two diastereomers were tested with the phenyl group located in either a trans (7, 9) or cis (8, 10) relationship with respect to the amine. After screening at a single concentration in the LSD1 enzyme inhibition assay, dose-response curves were determined for analogues with significant activity ( Table 1 ). The simplest analogues 7a and the cis diastereomer 8a feature the addition of a fluorine without further modifications. Although 7a and 8a are respectively three-fold more active or equipotent to tranylcypromine in MAO B inhibition, 22 a surprising loss of activity was observed for LSD1 inhibition. Meanwhile, the addition of methoxy, fluoro or trifluoromethyl groups to the phenyl ring of tranylcypromine is known to boost LSD1 inhibition. 14, 19, 24 We found that introduction of these substituents restored the ability to significantly inhibit LSD in the fluorinated analogues 7g, 9a, 9c, 9d and 10d. Finally, tranylcypromine analogues containing the Cl, NO 2 or SF 5 substituents are undisclosed as LSD1 inhibitors in the literature. Our results indicate all three functional groups are compatible with affinity for this target as 7h, 7i, 9b and 9e were micromolar inhibitors.
Three of the meta-substituted fluorinated analogues 9a-c together with a cis diastereomer 10c were selected for further evaluation in growth inhibition assays using the acute myeloid leukemia (AML) cell lines MV4-11 and THP-1 ( Table 2 ). The nitro-substituted analogue 9b was inactive in the tested concentration range whereas the methoxy-analogue 9a and both fluoro-diastereomers 9c and 10c were micromolar in potency. Although 9c differs from tranylcypromine only by the addition of two fluorine atoms, it is >100-fold more potent in the cell assay. We profiled the effects of 9a on the levels of biomarkers in MV4-11 cells to verify that the antiproliferative effect is due to the pharmacological suppression of LSD1. The compound exhibited a dose-dependent increase in H3K4me2 levels consistent with the inhibition of lysine demethylation (Fig 5A) . In addition, treatment with 9a increased the expression levels of CD86 (Fig 5B) , a cell surface biomarker recently proposed as a surrogate readout for LSD1 inhibition. 26 In summary, we have studied the effect of cyclopropyl ring fluorination on LSD1 activity within the tranylcypromine class of irreversible amine oxidase inhibitors. The addition of a fluorine atom to tranylcypromine by itself results in decreased LSD1 inhibition (unlike the increase in MAO inhibition). However, the introduction of an additional substitution in the phenyl ring has yielded a number of fluorinated LSD1 inhibitors that are more active than tranylcypromine. Overall, metasubstitution is preferred to para-as all five meta-analogues 9a-e displayed enhanced activity. Nevertheless, with the CF 3 -or SF 5 -substituents, the para-analogue was more active than its metacounterpart. Although the diastereomers that retained tranylcypromine's trans relationship between the aryl group and the amine (7 versus 8, 9 versus 10) were generally superior, in the case of 9c/10c and 9d/10d the differences were negligible. Selected compounds 9a, 9c and 10c inhibited cell proliferation in AML cell lines and increased the levels of the biomarkers H3K4me2 and CD86, supporting a LSD1-dependent cellular mechanism of action. Table 2 . IC50 of fluorinated tranylcypromines in cell growth proliferation assays, (72 h incubation) ± STD (n=5) with tranylcypromine 1 as a reference. 
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